Patents by Inventor Pascal Merchiers

Pascal Merchiers has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CD38 modulating antibody
    Patent number: 11542338
    Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD38. In particular, the present disclosure provides sequences of anti-human CD38 antibodies. Antibodies and antigen-binding portions thereof including such sequences present features compatible with pharmaceutical manufacturing and development can be provided as fully human antibodies (e.g., fully human monoclonal antibodies or antigen-binding fragments) that can be useful for medical methods and compositions, in particular for treating cancer.
    Type: Grant
    Filed: August 16, 2018
    Date of Patent: January 3, 2023
    Assignee: BLACK BELT THERAPEUTICS LIMITED
    Inventors: Anne Goubier, Josephine Salimu, Kevin Moulder, Beatriz Goyenechea Corzo, Simone Filosto, Pascal Merchiers, Nina Eissler, Hemanta Baruah, Bianka Prinz
  • CD38 antibody
    Patent number: 11236173
    Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD38. In particular, the present disclosure provides sequences of anti-human CD38 antibodies. Antibodies and antigen-binding portions thereof including such sequences present features compatible with pharmaceutical manufacturing and development can be provided as fully human antibodies (e.g., fully human monoclonal antibodies or antigen-binding fragments) that can be useful for medical methods and compositions, in particular for treating cancer.
    Type: Grant
    Filed: August 16, 2018
    Date of Patent: February 1, 2022
    Inventors: Anne Goubier, Josephine Salimu, Kevin Moulder, Beatriz Goyenechea Corzo, Simone Filosto, Pascal Merchiers, Nina Eissler, Hemanta Baruah, Bianka Prinz
  • CD38 MODULATING ANTIBODY AGENTS
    Publication number: 20210277138
    Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD38. In particular, the present disclosure provides sequences of anti-human CD38 antibodies. Antibodies and antigen-binding portions thereof including such sequences present features compatible with pharmaceutical manufacturing and development can be provided as fully human antibodies (e.g., fully human monoclonal antibodies or antigen-binding fragments) that can be useful for medical methods and compositions, in particular for treating cancer.
    Type: Application
    Filed: June 8, 2018
    Publication date: September 9, 2021
    Inventors: Pascal Merchiers, Anne Goubier, Kevin Moulder, Nina Eissler, Josephine Salimu, Simone Filosto, Beatriz Goyenchea Corzo, Hemanta Baruah, Bianka Prinz
  • ANTI-CD25 ANTIBODY AGENTS
    Publication number: 20210054084
    Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in 5 pharmaceutical compositions and methods of treatment, in particular for treating cancer.
    Type: Application
    Filed: March 13, 2019
    Publication date: February 25, 2021
    Inventors: Anne Goubier, Beatriz Goyenechea Corzo, Josephine Salimu, Kevin Moulder, Pascal Merchiers, Sergio Quezada
  • ANTI-CD25 FOR TUMOUR SPECIFIC CELL DEPLETION
    Publication number: 20210047420
    Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical compositions and methods of treatment, in particular for treating cancer.
    Type: Application
    Filed: March 13, 2019
    Publication date: February 18, 2021
    Inventors: Anne Goubier, Beatriz Goyenechea Corzo, Josephine Salimu, Kevin Moulder, Pascal Merchiers, Sergio Quezada
  • ANTI-CD25 FOR TUMOUR SPECIFIC CELL DEPLETION
    Publication number: 20210040221
    Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25, in particular an anti CD25-a-674 antibody which do not block the binding of CD25 to IL-2 or IL-2 signalling. The claimed antibody binds to the epitopes: YQCVQGYRALHRGP (150 to 163) or SVCKMTHGKTRWTQP (166 to 180) on CD25 Antibodies and antigen-binding portions N thereof including such sequences can be used in pharmaceutical compositions and methods of treatment, in particular for treating cancer.
    Type: Application
    Filed: March 13, 2019
    Publication date: February 11, 2021
    Inventors: Anne Goubier, Beatriz Goyenechea Corzo, Josephine Salimu, Kevin Moulder, Pascal Merchiers, Sergio Quezada
  • ANTI-CD25 FOR TUMOUR SPECIFIC CELL DEPLETION
    Publication number: 20210009703
    Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25, in particular an anti CD25-a-672 antibody which do not block the binding of CD25 to IL-2 or IL-2 signalling. The claimed antibody binds to the epitopes: PHATFKAMA YKEGTM (42-56) and YQCVQGYRALH (150-160) on CD25. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical compositions and methods of treatment, in particular for treating cancer.
    Type: Application
    Filed: March 13, 2019
    Publication date: January 14, 2021
    Inventors: Anne Goubier, Beatriz Goyenechea Corzo, Josephine Salimu, Kevin Moulder, Pascal Merchiers, Mark Brown, James Geoghegan, Bianka Prinz, Sergio Quezada
  • ANTI-CD25 FOR TUMOUR SPECIFIC CELL DEPLETION
    Publication number: 20210009702
    Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25, in particular an anti CD25-a-634 antibody which do not block the binding of CD25 to IL-2 or IL-2 signalling Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical compositions and methods of treatment, in particular for treating cancer.
    Type: Application
    Filed: March 13, 2019
    Publication date: January 14, 2021
    Inventors: Anne Goubier, Beatriz Goyenechea Corzo, Josephine Salimu, Kevin Moulder, Pascal Merchiers, Mark Brown, James Geoghegan, Bianka Prinz, Sergio Quezada
  • ANTI-CD25 FOR TUMOUR SPECIFIC CELL DEPLETION
    Publication number: 20210009704
    Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25, in particular an anti CD25-a-674 antibody which do not block the binding of CD25 to IL-2 or IL-2 signalling. The claimed antibody binds to the epitopes: QCVQGYRA and RWTQPQLICTG on CD25 Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical compositions and methods of treatment, in particular for treating cancer.
    Type: Application
    Filed: March 13, 2019
    Publication date: January 14, 2021
    Inventors: Anne Goubier, Beatriz Goyenechea Corzo, Josephine Salimu, Kevin Moulder, Pascal Merchiers, Mark Brown, James Geoghegan, Bianka Prinz, Sergio Quezada
  • ANTI-CD25 ANTIBODY AGENTS
    Publication number: 20210009699
    Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.
    Type: Application
    Filed: February 5, 2020
    Publication date: January 14, 2021
    Inventors: Anne Goubier, Beatriz Goyenechea Corzo, Josephine Salimu, Kevin Moulder, Pascal Merchiers, Mark Brown, Sergio Quezada, James Geoghegan, Bianka Prinz
  • ANTI-CD25 ANTIBODY AGENTS
    Publication number: 20200407454
    Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.
    Type: Application
    Filed: February 5, 2020
    Publication date: December 31, 2020
    Inventors: Anne Goubier, Beatriz Goyenechea Corzo, Josephine Salimu, Kevin Moulder, Pascal Merchiers, Mark Brown, Sergio Quezada, James Geoghegan, Bianka Prinz
  • Anti-CD25 antibody agents
    Patent number: 10752691
    Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: August 25, 2020
    Assignees: Tusk Therapeutics Ltd., Cancer Research Technology Limited
    Inventors: Anne Goubier, Beatriz Goyenechea Corzo, Josephine Salimu, Kevin Moulder, Pascal Merchiers, Mark Brown, Sergio Quezada, James Geoghegan, Bianka Prinz
  • Anti-CD25 antibody agents
    Patent number: 10745485
    Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: August 18, 2020
    Assignees: Tusk Therapeutics Ltd., Cancer Research Technology Limited
    Inventors: Anne Goubier, Beatriz Goyenechea Corzo, Josephine Salimu, Kevin Moulder, Pascal Merchiers, Mark Brown, Sergio Quezada, James Geoghegan, Bianka Prinz
  • Anti-CD25 antibody agents
    Patent number: 10738125
    Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: August 11, 2020
    Assignees: Tusk Therapeutics Ltd., Cancer Research Technology Limited
    Inventors: Anne Goubier, Beatriz Goyenechea Corzo, Josephine Salimu, Kevin Moulder, Pascal Merchiers, Mark Brown, Sergio Quezada, James Geoghegan, Bianka Prinz
  • ANG2-BINDING MOLECULES
    Publication number: 20200207845
    Abstract: Ang2-binding molecules, preferably Ang2-binding immunoglobulin single variable domains like VHHs and domain antibodies, pharmaceutical compositions containing same and their use in the treatment of diseases that are associated with Ang2-mediated effects on angiogenesis. Nucleic acids encoding Ang2-binding molecules, host cells and methods for preparing same.
    Type: Application
    Filed: March 13, 2020
    Publication date: July 2, 2020
    Inventors: Rene Georg Ott, Eric Borges, Andreas Gschwind, Joachim Boucneau, Marie-Ange Buyse, Erik Depla, Pascal Merchiers, Frederik Stevenaert
  • CD38 MODULATING ANTIBODY
    Publication number: 20200190209
    Abstract: The present disclosure provides antibodies that bind to human CD38. In particular, the antibodies and antigen-binding portions thereof are defined by particular functional characteristics. The antibodies present features compatible for manufacturing and can be provided as fully human antibodies (e.g., fully human monoclonal antibodies or antigen-binding fragments) that can be useful for medical methods and compositions, in particular for treating cancer.
    Type: Application
    Filed: June 8, 2018
    Publication date: June 18, 2020
    Inventors: Pascal Merchiers, Anne Goubier, Kevin Moulder, Nina Eissler, Josephine Salimu, Simone Filosto, Beatriz Goyenechea Corzo, Hemanta Baruah, Bianka Prinz
  • FC-OPTIMIZED ANTI-CD25 FOR TUMOR SPECIFIC CELL DEPLETION
    Publication number: 20200010554
    Abstract: The present disclosure relates to use of an anti-CD25 antibody, not inhibiting IL-2-CD25 interaction, with enhanced binding to activating Fc gamma Rs that lead to effective depletion of tumor-infiltrating Treg cells and improved control of established tumors. Combination with anti-programmed cell death protein-1 antibodies further improves tumor rejection.
    Type: Application
    Filed: March 3, 2018
    Publication date: January 9, 2020
    Inventors: Anne Goubier, Josephine Salimu, Kevin Moulder, Beatriz Goyenechea Corzo, Pascal Merchiers, Sergio Quezada, Karl Peggs, Frederick Arce Vargas, Isabelle Solomon
  • ANTI-CD25 ANTIBODY AGENTS
    Publication number: 20190322752
    Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.
    Type: Application
    Filed: March 13, 2019
    Publication date: October 24, 2019
    Inventors: Anne Goubier, Beatriz Goyenechea Corzo, Josephine Salimu, Kevin Moulder, Pascal Merchiers, Mark Brown, Sergio Quezada, James Geoghegan, Blanka Prinz
  • ANTI-CD25 ANTIBODY AGENTS
    Publication number: 20190284287
    Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.
    Type: Application
    Filed: March 13, 2019
    Publication date: September 19, 2019
    Inventors: Anne Goubier, Beatriz Goyenechea Corzo, Josephine Salimu, Kevin Moulder, Pascal Merchiers, Mark Brown, Sergio Quezada, James Geoghegan, Bianka Prinz
  • ANG2-BINDING MOLECULES
    Publication number: 20190135907
    Abstract: Ang2-binding molecules, preferably Ang2-binding immunoglobulin single variable domains like VHHs and domain antibodies, pharmaceutical compositions containing same and their use in the treatment of diseases that are associated with Ang2-mediated effects on angiogenesis. Nucleic acids encoding Ang2-binding molecules, host cells and methods for preparing same.
    Type: Application
    Filed: July 2, 2018
    Publication date: May 9, 2019
    Inventors: Rene Georg Ott, Eric Borges, Andreas Gschwind, Joachim Boucneau, Marie-Ange Buyse, Erik Depla, Pascal Merchiers, Frederik Stevenaert